Altering the genome with targeted nucleases is powerful and increasingly necessary for research and drug discovery. The CRISPR-Cas9 system has gained popularity due to its simplicity and high efficiency. However, the CRISPR technology has been plagued by problems with off-target mutations, a concern for research and drug discovery applications as it may compromise results.
The NextGEN™ CRISPR technology, developed by a member of Transposagen's Scientific Advisory Board (SAB), is the first truly dimeric RNA-guided FokI nuclease. NextGEN™ CRISPR technology has all the advantages of the CRISPR-Cas9 system, but has eliminated the problems with off-site targeting. The NextGEN™ CRISPR technology has also removed some of the design restrictions associated with the original system, thereby greatly increasing the number of sites that can be targeted.
The NextGEN™ CRISPR technology was described in an online publication in Nature Biotechnology released today entitled, “Dimeric CRISPR RNA-guided FokI Nucleases for Efficient Genome Editing.”1 The NextGEN™ CRISPR genome engineering tools and services provided by Transposagen are ideal when research and drug discovery applications require clean, high-precision genome editing. NextGEN™
CRISPR technology can be combined with Transposagen’s Footprint-Free™ Gene Editing systems, the only commercially available method capable of editing as little as a single nucleotide in nearly any genome without any unwanted mutations and with the ability to select for rare events.